Cue Biopharma Announces Completion of Patient Enrollment in

Completed enrollment of patient expansion cohort of 20 patients at the RP2D of 4 mg/kg in combination with KEYTRUDA® (pembrolizumab) in first line...

Related Keywords

Boston , Massachusetts , United States , Maya Romanchuck , Matteo Levisetti , Marie Campinell , Daniel Passeri , Corporate Communications , Securities Exchange , Cue Biopharma Inc , Society For Immunotherapy Of Cancer , Nasdaq , Drug Administration , Lifesci Communications , Twitter , Neck Cancer , Annual Meeting , Fast Track Designation , Cue Biopharma , Wilm Tumor , Selective Targeting , Securities Act , Securities Exchange Act , Risk Factors , Financial Condition , Annual Report , Quarterly Report ,